SCHEMBL26240299

SCHEMBL26240299

CC(=O)NC(CNc1nc(-c2ccc(Cl)c(Cl)c2)c(CC(C)C)s1)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRN P28799 1/20 0.40
▸ SORT1 Q99523 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ PTGDR2 Q9Y5Y4 5/20 0.39
▸ FBP1 P09467 2/20 0.38
▸ TP53 P04637 1/20 0.35
▸ BRAF P15056 2/20 0.35
▸ PDE4A P27815 2/20 0.35
▸ PDE4B Q07343 2/20 0.35
▸ PDE4C Q08493 2/20 0.35
▸ PDE4D Q08499 2/20 0.35
▸ DHODH Q02127 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23792015 0.91 GRN (0.40) GRNSORT1ABL1NPC1LMNA
SCHEMBL30173796 0.89 GRN (0.47) GRNSORT1NPC1LMNAPOLB
SCHEMBL23782529 0.89 GRN (0.47) GRNSORT1NPC1LMNAPOLB
SCHEMBL23792019 0.89 GRN (0.38) GRNSORT1ABL1NPC1LMNA
SCHEMBL23792000 0.88 FPR2 (0.45) GRNSORT1NPC1LMNAPOLB
SCHEMBL23791724 0.88 DHODH (0.42) GRNSORT1NPC1LMNAPOLB
SCHEMBL23792013 0.87 GRN (0.41) GRNSORT1NPC1LMNAPOLB
SCHEMBL23782338 0.87 ACE (0.37) GRNSORT1NPC1LMNAPOLB
SCHEMBL23792017 0.87 MEN1 (0.41) GRNSORT1NPC1LMNAPOLB
SCHEMBL23791772 0.85 PTGDR2 (0.46) GRNSORT1NPC1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 GRN 1587/4885SORT1 4202/4885ABL1 888/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 GRN 1587/4885SORT1 4202/4885ABL1 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback